8-K: Perspective Therapeutics Updates NET Trial Data at ASCO-GI

Perspective Therapeutics announced updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT--NET for neuroendocrine tumors, showing continued tolerability and durable disease control.

Summary

• Updated interim results for [212Pb]VMT--NET in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) were presented at the 2026 ASCO Gastrointestinal Cancers Symposium.
• The data cut-off date for the ASCO-GI update was December 10, 2025, with an additional approximately 13 weeks of follow-up since the prior ESMO 2025 update.
• Safety data includes 56 patients across three dose cohorts: 2 patients in Cohort 1 (2.5 mCi), 46 patients in Cohort 2 (5.0 mCi), and 8 patients in Cohort 3 (6.0 mCi).
• Efficacy analysis is based on 2 patients in Cohort 1 and 23 (half) of the patients in Cohort 2.
• [212Pb]VMT--NET continues to be well-tolerated with no dose limiting toxicities (DLTs), treatment-related discontinuations, serious renal complications, dysphagia, or clinically significant treatment-related myelosuppression reported.
• Grade 3 or higher treatment-emergent adverse events occurred in 21 patients (37.5%), including one transient Grade 4 lymphocyte count decrease in a Cohort 3 patient, which resolved without intervention.
• Serious adverse events were reported in five patients, none deemed related to the study medication.
• 76% (19 of 25) of patients in the efficacy analysis (Cohort 1 and half of Cohort 2) were without progression and remained alive.
• Objective response per RECIST v1.1 was observed in 39% (9 of 23) of patients in Cohort 2, including 8 previously confirmed responders and one new initial response pending confirmation.
• Seven patients showed deepening of best response, including one patient with stable disease.
• Cohort 3 (6.0 mCi) DLT assessment is complete, and the company is cleared to treat more patients, with one additional patient already treated.

Sentiment

Score: 8

Explanation: The updated interim clinical trial data for [212Pb]VMT--NET shows continued positive safety and efficacy signals, including durable disease control and deepening responses. The completion of DLT assessment for a higher dose cohort and plans for regulatory engagement in 2026 are strong positive indicators for the program's advancement.

Positives

• [212Pb]VMT--NET continues to be well-tolerated across all dose cohorts (2.5 mCi, 5.0 mCi, 6.0 mCi).
• No dose limiting toxicities (DLTs), treatment-related discontinuations, serious renal complications, dysphagia, or clinically significant treatment-related myelosuppression were reported.
• 76% of patients (19 out of 25) in the efficacy analysis were without progression and remained alive after an additional approximately 13 weeks of follow-up.
• Objective response rate of 39% (9 out of 23 patients) in Cohort 2, including one new initial response and 8 previously confirmed responders.
• Seven patients showed deepening of best response, indicating sustained anti-tumor activity.
• Cohort 3 (6.0 mCi) DLT assessment completed as planned, clearing the way for treating more patients at a potentially higher dose.
• The company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator.

Negatives

• Grade 3 or higher treatment-emergent adverse events were reported in 21 patients (37.5%).
• One patient in Cohort 3 experienced a transient Grade 4 lymphocyte count decrease, although it resolved without medical intervention.
• Five patients reported serious adverse events, though none were deemed related to the study medication.
• Efficacy data for the remaining 23 patients in Cohort 2 and 8 patients in Cohort 3 are still pending.

Risks

• Clinical trials may be more costly or take longer to complete than anticipated, or may never be completed.
• Clinical trials may not generate results that warrant future development of the tested product candidate.
• The company may elect to change its strategy regarding its product candidates and clinical development activities.
• Economic and market conditions may worsen.
• Risks related to the sufficiency of the company's cash resources for its future operating expenses and capital expenditures.

Future Outlook

Submissions to more medical conferences in 2026 are planned. Regulatory engagement is planned for 2026 to discuss proceeding with VMT--NET into a registrational trial. Initial efficacy data for another 23 patients in Cohort 2 and 8 patients in Cohort 3 are pending. The company remains focused on executing efficiently and delivering meaningful clinical advances for patients, applying insights from lead programs across the pipeline and strengthening internal clinical and manufacturing infrastructure.

Management Comments

• "With longer follow-up and a growing body of clinical experience, we continue to see evidence of sustained and deepening anti-tumor activity for VMT--NET at the dose level evaluated in Cohort 2, while the favorable tolerability profile is maintained, possibly even at a higher dose." Vikas Prasad, MD, Professor of Radiology, Mallinckrodt Institute of Radiology, Siteman Cancer Center, Washington University School of Medicine.
• "These data further support continued dose optimization, and I look forward to discussing the evolving results with the gastrointestinal oncology community as this study progresses." Vikas Prasad, MD.
• "The updated interim results presented at ASCO-GI continue to support VMT--NETs compelling overall clinical profile at the 5 mCi dose." Markus Puhlmann, Chief Medical Officer of Perspective.
• "Meanwhile, for the slightly higher dose (6 mCi), DLT assessment was completed and we are cleared to enroll more patients with one additional patient already treated." Markus Puhlmann.
• "With the robust clinical dataset being accrued from strong patient enrollment into our study, we believe we will be able to have meaningful engagement with regulatory agencies during 2026 on proceeding with VMT--NET into a registrational trial." Markus Puhlmann.
• "The continued progress of the VMT--NET program reflects both the strength of our targeted radiopharmaceutical technology platform and our growing capabilities as a clinical-stage oncology company." Thijs Spoor, Chief Executive Officer of Perspective.
• "As we apply insights from our lead programs across the pipeline and further strengthen our internal clinical and manufacturing infrastructure, we remain focused on executing efficiently and delivering meaningful clinical advances for patients." Thijs Spoor.

Industry Context

The company is a radiopharmaceutical development company pioneering advanced treatments for cancers, utilizing the alpha-emitting isotope 212Pb and a "theranostic" approach (see and treat). This positions them in a growing segment of oncology focused on targeted radiation therapies, which aim to improve efficacy and minimize toxicity compared to traditional treatments. The presentation at ASCO-GI, a major gastrointestinal cancers symposium, highlights the relevance of their drug candidate within the broader oncology community.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results, potentially increasing company valuation and future revenue prospects.
• Patients: Potential for a new, effective, and well-tolerated treatment option for unresectable or metastatic SSTR2-expressing neuroendocrine tumors.
• Employees: Continued progress in clinical development and strengthening infrastructure could lead to job stability and growth opportunities.
• Regulatory Authorities: Will be engaged in 2026 regarding the path to a registrational trial, indicating significant progress towards market approval.

Next Steps

• Submissions for presentations at additional medical conferences during 2026 are planned.
• Regulatory engagement during 2026 on proceeding with VMT--NET into a registrational trial.
• Initial efficacy data for the remaining 23 patients in Cohort 2 and eight patients in Cohort 3 are pending.
• Continue to apply insights from lead programs across the pipeline.
• Further strengthen internal clinical and manufacturing infrastructure.

Key Dates

Recommendation

The updated interim Phase 1/2a clinical trial data for [212Pb]VMT--NET demonstrates a compelling clinical profile with strong safety and efficacy signals, including durable disease control and objective responses in a significant portion of patients. The successful completion of DLT assessment for a higher dose cohort and clear plans for regulatory engagement in 2026 for a registrational trial indicate significant de-risking and a clear path forward for this promising radiopharmaceutical. These positive developments, coupled with the company's growing capabilities and theranostic platform, suggest substantial future value creation.

Keywords

Radiopharmaceutical, Neuroendocrine Tumors, NETs, SSTR2, [212Pb]VMT--NET, Phase 1/2a, Clinical Trial, Oncology, Cancer Treatment, Alpha-emitting isotope, Theranostics, ASCO-GI, CATX, Perspective Therapeutics